IN2014CH00393A - - Google Patents

Info

Publication number
IN2014CH00393A
IN2014CH00393A IN393CH2014A IN2014CH00393A IN 2014CH00393 A IN2014CH00393 A IN 2014CH00393A IN 393CH2014 A IN393CH2014 A IN 393CH2014A IN 2014CH00393 A IN2014CH00393 A IN 2014CH00393A
Authority
IN
India
Prior art keywords
peptide
support
adhesive layer
cellular immunity
tape preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Yoshiki Maeda
Katsuyuki Okubo
Daisuke Asari
Arimichi Okazaki
takuya Shishido
Mitsuhiko Hori
Haruo Sugiyama
Original Assignee
Nitto Denko Corp
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp, Univ Osaka filed Critical Nitto Denko Corp
Publication of IN2014CH00393A publication Critical patent/IN2014CH00393A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001152Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN393CH2014 2013-02-05 2014-01-29 IN2014CH00393A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013020798 2013-02-05

Publications (1)

Publication Number Publication Date
IN2014CH00393A true IN2014CH00393A (fr) 2015-04-03

Family

ID=50028734

Family Applications (1)

Application Number Title Priority Date Filing Date
IN393CH2014 IN2014CH00393A (fr) 2013-02-05 2014-01-29

Country Status (8)

Country Link
US (1) US10195258B2 (fr)
EP (1) EP2762156A1 (fr)
JP (1) JP6512569B2 (fr)
KR (1) KR102050931B1 (fr)
CN (1) CN103961305B (fr)
CA (1) CA2841014A1 (fr)
IN (1) IN2014CH00393A (fr)
RU (1) RU2697443C2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626238C (fr) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides
EP3834836A1 (fr) 2006-04-10 2021-06-16 Memorial Sloan Kettering Cancer Center Peptides wt-1 immunogènes et leurs utilisations
EP2802347B1 (fr) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Peptides wt-1 immunogènes et leurs procédés d'utilisation
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN116789792A (zh) 2013-01-15 2023-09-22 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
JP6512568B2 (ja) * 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用wt1ペプチド癌ワクチン組成物
JP2016074654A (ja) * 2014-10-02 2016-05-12 日東電工株式会社 経皮投与用ワクチン医薬組成物
DE102015119789A1 (de) * 2015-11-16 2017-05-18 Denso-Holding Gmbh & Co. Korrosionsschutzzusammensetzung umfassend Polyisobutylene
JPWO2022030631A1 (fr) * 2020-08-07 2022-02-10
CN114712493B (zh) * 2022-04-29 2024-05-28 华南理工大学 一种疫苗递送载体及其制备方法和应用
WO2024088383A1 (fr) * 2022-10-28 2024-05-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anticorps anti-wt1/hla et leurs utilisations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
RU2192884C2 (ru) 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US20040109869A1 (en) * 2001-03-19 2004-06-10 Iomai Corporation Transcutaneous immunostimulation
CA2440303C (fr) 2001-03-22 2013-03-19 Haruo Sugiyama Peptide modifie wt1
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
CN101113163B (zh) 2002-06-12 2010-10-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
DE60329201D1 (de) 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
KR20130062368A (ko) 2003-11-05 2013-06-12 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Wt1 유래의 hla-dr 결합성 항원 펩티드
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
WO2005089777A1 (fr) 2004-03-15 2005-09-29 Karaolis David K R Procede inhibant la proliferation et accroissant l'apoptose de cellules cancereuses
PL1731605T3 (pl) 2004-03-31 2010-08-31 Int Inst Cancer Immunology Inc Nowotworowe peptydy antygenowe pochodzące z WT1
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1782826A1 (fr) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS, c-diGMP et leurs conjugués utilisés comme adjuvants et leur emploi dans des compositions pharmaceutiques
CA2631292C (fr) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Peptides antigenes de cancer wt1 derives et leur utilisation
SI1988163T1 (sl) 2006-02-22 2012-09-28 Int Inst Cancer Immunology Inc HLA-A*3303-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
JP4925039B2 (ja) 2006-09-21 2012-04-25 日東電工株式会社 糖材料の調製方法ならびに糖材料、糖材料を含むマイクロニードルおよびマイクロニードルをそなえてなる経皮製剤
JP2008127277A (ja) * 2006-11-16 2008-06-05 Osaka Prefectural Hospital Organization 免疫賦活化促進剤
NZ592510A (en) 2006-12-28 2012-11-30 Int Inst Cancer Immunology Inc HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
EP2123296B1 (fr) * 2007-01-31 2019-05-22 Hisamitsu Pharmaceutical Co., Inc. Adjuvant pour administration transdermique ou transmucosale et preparation pharmaceutique le contenant
WO2009046738A1 (fr) * 2007-10-09 2009-04-16 Curevac Gmbh Composition pour traiter le cancer du poumon, notamment les cancers du poumon non à petites cellules (nsclc)
US8557779B2 (en) * 2007-12-05 2013-10-15 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
CA2777400C (fr) * 2009-10-12 2018-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysine dans l'immunotherapie
ES2655031T3 (es) * 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
KR20140100422A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 백신 조성물
JP6512568B2 (ja) * 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用wt1ペプチド癌ワクチン組成物
CA2840997A1 (fr) * 2013-02-05 2014-08-05 Nitto Denko Corporation Composition de vaccin pour administration transdermique

Also Published As

Publication number Publication date
RU2014102937A (ru) 2015-08-10
KR102050931B1 (ko) 2019-12-02
CN103961305A (zh) 2014-08-06
JP6512569B2 (ja) 2019-05-15
CA2841014A1 (fr) 2014-08-05
CN103961305B (zh) 2019-10-18
EP2762156A1 (fr) 2014-08-06
US10195258B2 (en) 2019-02-05
US20140220105A1 (en) 2014-08-07
JP2014169279A (ja) 2014-09-18
RU2697443C2 (ru) 2019-08-14
KR20140100421A (ko) 2014-08-14

Similar Documents

Publication Publication Date Title
IN2014CH00393A (fr)
IN2014CH00396A (fr)
HK1261924A1 (zh) 用於實施治療,如癌症治療的控制器和柔性線圈
IN2014CH00391A (fr)
SG10201900693TA (en) Pressure-sensitive adhesive sheet
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MY167716A (en) Drive device
IN2014CH00395A (fr)
MX357202B (es) Composicion de particula tipo virus.
EP3150202A4 (fr) Vecteur de médicament destiné à l'administration d'un médicament ciblé spécifique d'une tumeur et utilisation associée
MX2016003876A (es) Métodos y aparatos para suministrar moléculas a través de capas de tejidos.
MY156697A (en) Modified tuberculosis antigens
MX2015016755A (es) Reagrupamiento del virus de influenza.
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
SG10201805806RA (en) Modulation of Structured Polypeptide Specificity
IN2014DN05885A (fr)
MX2015016627A (es) Vacuna para la malaria.
EP3661541A4 (fr) Méthodes de thérapie génique ciblant le facteur viii (fviii)
MX2015011837A (es) Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada.
MX2016005285A (es) Conjugados de somatostatina y sus analagos.
PH12015501854A1 (en) Factor ix polypeptide formulations
MY165824A (en) Induction Motor and Ceiling Fan Including the Same
EP3709946A4 (fr) Système de levage de patient portable